Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Hyaluronate In Bronchoalveolar Lavage Fluid: A New Marker In Sarcoidosis Reflecting Pulmonary Disease

Roger Hällgren, Anders Eklund, Anna Engström-Laurent and Birgitta Schmekel
British Medical Journal (Clinical Research Edition)
Vol. 290, No. 6484 (Jun. 15, 1985), pp. 1778-1781
Published by: BMJ
Stable URL: http://www.jstor.org/stable/29519517
Page Count: 4
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Hyaluronate In Bronchoalveolar Lavage Fluid: A New Marker In Sarcoidosis Reflecting Pulmonary Disease
Preview not available

Abstract

Hyaluronate (hyaluronic acid) was not detectable in bronchoalveolar lavage fluid from smoking or non-smoking healthy volunteers but was present in fluid from 23 patients with sarcoidosis; the mean concentration was 16 μg/1 returned fluid (range ≤5-430) or, expressed in relation to the amount of albumin recovered, 0.22 μg/mg albumin (range ≤0.05-3.6). The serum hyaluronate concentrations in the patients with sarcoidosis were normal. There was a significant inverse correlation between vital lung capacity and hyaluronate concentrations in bronchoalveolar lavage fluid (p<0.001), and patients with abnormal lung volumes had hyaluronate concentrations that were on average six times higher than those in patients with normal vital capacity. Duration of disease, pulmonary radiological findings, and markers for macrophage activation (angiotensin converting enzyme) and lymphocyte activation (β₂ microglobulin) were not correlated with bronchoalveolar lavage fluid hyaluronate. It was concluded that in sarcoidosis release of hyaluronate into the airways is related to lung volume and therefore to the course of the disease. Increased synthesis of hyaluronate in lung parenchyma may reflect activation of fibroblasts, and measurements of hyaluronate may have clinical value for prognosis and treatment.

Page Thumbnails

  • Thumbnail: Page 
1778
    1778
  • Thumbnail: Page 
1779
    1779
  • Thumbnail: Page 
1780
    1780
  • Thumbnail: Page 
1781
    1781